US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Xtrackers Nifty 500 India ETF

21.07

-0.2750-1.29%

Volume:461

Turnover:10K

Market Cap:4.21M

PE:- -

High:21.07

Open:21.31

Low:21.07

Close:21.35

52wk High:27.40

52wk Low:20.52

Shares:200.00K

Float Shares:200.00K

Volume Ratio:0.72

T/O Rate:0.23%

Dividend:0.08

Dividend Rate:0.37%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Industrial Minerals Sets AGM to Vote on Director Re-Election and Extra Capital Raising Headroom

Industrial Minerals Secures North Pool Tenement, Prepares Maiden Drilling at Laverton

Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND

Press Release: Avacta Group Plc: Interim Results for the Six Months to June 30, 2026, and Business Update

Press Release: MaaT Pharma Publishes Its Half-Year 2026 Results and Provides a Business Update

NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes

Quantum BioPharma (NASDAQ: QNTM) Receives FDA Green Light to Move Lucid-MS into Phase 2 Testing

Prime Medicine announces FDA clearance of IND application for PM647

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency

Press Release: Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (fshd) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development

Kringle Pharma Submits IND Application for Spinal Cord Injury Drug to U.S. FDA; Shares Jump 7%

MT Newswires Live

Press Release: Sensorion Reports 2026 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report

Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager

Nomura Predicts India's Central Bank Net Forward Short Position Could Reach $232.3 Billion

KBI DONGKOOK Extends KRW 17 Billion Debt Guarantee for German Auto Subsidiary

Claim of 15.9 Million Turned Into a 150,000 Award: Court Fees Leave Plaintiff Holding Over 99% of the Tab in Drug Partner Dispute

Xortx Therapeutics announces planned FDA IND submission for XRx-026

JPMorgan Warns of India's Short-Term Economic Euphoria, Urges RBI Caution on Rate Hikes

NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution

Industrial Minerals Sets AGM Date and Board Nomination Deadline

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/IND/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IND","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","market":"US","secType":"STK","nameCN":"Xtrackers Nifty 500 India ETF","latestPrice":21.07,"timestamp":1791489600000,"preClose":21.345,"halted":0,"volume":461,"delay":0,"changeRate":-0.012883579292574308,"floatShares":200001,"shares":200001,"eps":0,"marketStatus":"Pre-Mkt","change":-0.275,"latestTime":"10-09 08:18:20 EDT","open":21.31,"high":21.07,"low":21.07,"amount":9755,"amplitude":0,"askPrice":25,"askSize":4,"bidPrice":18.02,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791552600000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":21.07,"sharesOutstanding":200001,"nav":21.341,"aum":4268288.54,"dividendRate":0.003749,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":21.345,"preClose":21.07,"latestTime":"16:10 EDT","volume":7,"amount":147.49,"timestamp":1791490204237,"change":0.275,"changeRate":0.013052,"amplitude":0},"volumeRatio":0.7158385315477805},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","floatShares":200001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.7158385315477805,"shares":200001,"dividePrice":0.079,"high":21.07,"amplitude":0,"preClose":21.345,"low":21.07,"week52Low":20.515,"pbRate":"--","week52High":27.4,"institutionHeld":0,"latestPrice":21.07,"committee":0.923077,"eps":0,"divideRate":0.003749,"volume":461,"delay":0,"ttmEps":0,"open":21.31,"prevYearClose":24.78,"prevWeekClose":21.5,"prevMonthClose":21.62,"prevQuarterClose":21.62,"fiveDayClose":21.5042,"twentyDayClose":22.465,"sixtyDayClose":22.79},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IND\",params:#limit:5,,,undefined,":[{"date":"2026-06-18","symbol":"IND","amount":0.07775,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-18","defaultRemindTime":1781789400000,"name":"Xtrackers Nifty 500 India ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-18","currency":"USD","dateTimestamp":1781755200000,"payDate":"2026-06-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IND\",market:\"US\",,,undefined,":[{"executeDate":"2026-06-18","recordDate":"2026-06-18","paymentDate":"2026-06-26","value":0.07775,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IND\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IND\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672273959","title":"Industrial Minerals Sets AGM to Vote on Director Re-Election and Extra Capital Raising Headroom","url":"https://stock-news.laohu8.com/highlight/detail?id=2672273959","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672273959?lang=en_us&edition=fundamental","pubTime":"2026-10-01 10:49","pubTimestamp":1790822949,"startTime":"0","endTime":"0","summary":"Industrial Minerals Limited ( ($AU:IND) ) has issued an announcement. Industrial Minerals Limited has called its annual general meeting for 17 Nove...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-sets-agm-to-vote-on-director-re-election-and-extra-capital-raising-headroom?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-sets-agm-to-vote-on-director-re-election-and-extra-capital-raising-headroom?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IND","BK4109","MTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672738919","title":"Industrial Minerals Secures North Pool Tenement, Prepares Maiden Drilling at Laverton","url":"https://stock-news.laohu8.com/highlight/detail?id=2672738919","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672738919?lang=en_us&edition=fundamental","pubTime":"2026-10-01 06:55","pubTimestamp":1790808916,"startTime":"0","endTime":"0","summary":"The latest update is out from Industrial Minerals Limited ( ($AU:IND) ). Industrial Minerals Ltd has secured Exploration Licence E38/4061 for the N...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-secures-north-pool-tenement-prepares-maiden-drilling-at-laverton?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-secures-north-pool-tenement-prepares-maiden-drilling-at-laverton?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MTX","IND","BK4109"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671202674","title":"Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND","url":"https://stock-news.laohu8.com/highlight/detail?id=2671202674","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671202674?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:32","pubTimestamp":1790771520,"startTime":"0","endTime":"0","summary":"Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed no","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/30/3371881/0/en/ernexa-therapeutics-reports-compelling-erna-101-safety-results-across-three-critical-ind-enabling-studies-advancing-toward-planned-q4-2026-ind.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4139","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671320189","title":"Press Release: Avacta Group Plc: Interim Results for the Six Months to June 30, 2026, and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2671320189","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671320189?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:00","pubTimestamp":1790769600,"startTime":"0","endTime":"0","summary":"LONDON and PHILADELPHIA, Sept. 30, 2026  -- Avacta Therapeutics , a life sciences company developing innovative, targeted oncology drugs, today publishes its unaudited interim results for the six months ended June 30, 2026 .H1 highlights and post periodResearch & developmentNext Generation pre|CISION pipeline-- AVA6103 . -- Preliminary preclinical and clinical data with AVA6103 have been. presented recently. Data reported in the Phase 1a trial in. patients with select solid tumors demonstrate proof of mechanism. demonstrates a clean safety profile through the first three. dose levels, including a payload dose level 50% higher than. -- The comparison of the preclinical modeled pharmacokinetic.  data and clinical trial PK data demonstrates an. exceptional alignment through the first 3 dose levels with. controlled release of exatecan evident in patients for days. -- The first head-to-head preclinical comparison of AVA6103 and. Enhertu, a marketed antibody drug conjugate  that targets. HER","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4231","BK4585","IE00BFXG0V08.USD","IE00B5TLWC47.USD","LU2413666699.HKD","LU1093756325.SGD","IE00BYQQ9H92.USD","BK4588","LU2211817866.USD","LU2413666426.HKD","LU0347712357.USD","KBWY","R","BK4232","BK4121","ADC","LU1721428933.USD","BK4181","LU1093756168.USD","BK4123","IND","BK4218","PK","BK4533","MTD","NETL","BK4080","BK4567","AVCTF","PDC","BK4022","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671245482","title":"Press Release: MaaT Pharma Publishes Its Half-Year 2026 Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2671245482","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671245482?lang=en_us&edition=fundamental","pubTime":"2026-09-30 00:00","pubTimestamp":1790697600,"startTime":"0","endTime":"0","summary":"--  In September 2026, following the re-examination procedure, the. CHMP maintained its negative opinion on the Conditional Marketing. --  Feedback received through a Type C interaction with the U.S.Food and Drug Administration  contributes to the preparation. of PHOENIX as a proposed registrational Phase 3 trial and provides. a framework for finalizing the protocol and progressing U.S.H1 2025, mostly driven by the impact of the Clinigen Licensing Agreement. as of January 1, 2026, while patient demand in the Early Access Program. --  Cash runway now estimated to extend to December 2026 based on the. authorizations have been given under the Early Access Program in 14. --  In March 2026, at the European Society for Blood and Marrow. results from the ARES trial evaluating MaaT013  in aGvHD.The Company also presented CHRONOS real-world data, reporting 29%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989772840.SGD","R","BK4081","BK4232","EBMT","BK4211","SPRE","LU1989771016.USD","BK4585","BK4555","TM","EMA","BK4588","MET","03160","BK4022","BK4162","BK4099","BK4604","MAA","IND","LU1496350502.SGD","LU1291159041.SGD","LU1989772923.USD","BK4215"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670324452","title":"NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2670324452","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670324452?lang=en_us&edition=fundamental","pubTime":"2026-09-28 20:00","pubTimestamp":1790596800,"startTime":"0","endTime":"0","summary":"Following successful FDA Pre-IND meeting, NewcelX advances IND-enabling activities for NCEL-101ZURICH, Sept.  28, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL), a regenerative medicine company ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/28/3369832/0/en/newcelx-management-to-attend-breakthrough-t1d-congress-in-philadelphia-advancing-its-mission-to-develop-a-cure-for-type-1-diabetes.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443622.USD","IE00B1BXHZ80.USD","LU2237443382.USD","LU2237443895.HKD","LU2746668461.USD","BK4006","LU0149725797.USD","IE00BHPRN162.USD","LU0267386448.USD","LU1363072403.SGD","LU0971096721.USD","LU2237443465.HKD","LU0234572021.USD","LU0170899867.USD","IE00BKVL7J92.USD","LU2746668974.SGD","IE00BFXG1179.USD","IE00BZ1G4Q59.USD","LU0882574139.USD","LU2237443549.SGD","CMC","IND","LU2237443978.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670463425","title":"Quantum BioPharma (NASDAQ: QNTM) Receives FDA Green Light to Move Lucid-MS into Phase 2 Testing","url":"https://stock-news.laohu8.com/highlight/detail?id=2670463425","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670463425?lang=en_us&edition=fundamental","pubTime":"2026-09-25 23:30","pubTimestamp":1790350237,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, September 25th, 2026, FinanceWire The FDA IND approval marks a pivotal step for the company’s lead compound, kn...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/quantum-biopharma-nasdaq-qntm-receives-fda-green-light-to-move-lucid-ms-into-phase-2-testing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/quantum-biopharma-nasdaq-qntm-receives-fda-green-light-to-move-lucid-ms-into-phase-2-testing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QQQM","QQQJ","LCIZ","TQQY","LCID","QQQE","FTEC","QQQY","TECS","QYLG","IND",".IXIC","QQQA","BK4007","QID","NDX","BK4596","SQQQ","MNQmain","ONEQ","NQmain","QQQ","LCDL","QLD","BK4588","PSQ","03086","LABU","BK4551","JEPQ","GPIQ","BK4585","BK4099","NVIW.SI","TQQQ","IYW","QDTE","BK4555","QNTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670629418","title":"Prime Medicine announces FDA clearance of IND application for PM647","url":"https://stock-news.laohu8.com/highlight/detail?id=2670629418","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670629418?lang=en_us&edition=fundamental","pubTime":"2026-09-25 04:05","pubTimestamp":1790280337,"startTime":"0","endTime":"0","summary":"Prime Medicine (PRME) announced that the FDA has cleared the company’s Investigational New Drug, or IND, application for PM647, an investigational ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/prime-medicine-announces-fda-clearance-of-ind-application-for-pm647-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/prime-medicine-announces-fda-clearance-of-ind-application-for-pm647-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRME","IND","BK4585","LABU","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670183504","title":"Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2670183504","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670183504?lang=en_us&edition=fundamental","pubTime":"2026-09-25 04:01","pubTimestamp":1790280060,"startTime":"0","endTime":"0","summary":"-- Clearance highlights continued execution, modularity and momentum across Prime Medicine’s liver franchise, building on recent regulatory clearances for PM577a -- -- Initial clinical data expected i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/24/3368730/0/en/prime-medicine-announces-u-s-fda-clearance-of-investigational-new-drug-application-for-pm647-in-alpha-1-antitrypsin-deficiency.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","BK4588","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669646251","title":"Press Release: Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (fshd) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2669646251","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669646251?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:00","pubTimestamp":1790247600,"startTime":"0","endTime":"0","summary":"-- FDA clearance expands development of forazapadin into a second. degenerative muscle disease with significant unmet medical need. -- FSHD Canada Foundation to provide up to US$5 million in non-dilutive. financing toward the clinical development of forazapadin in FSHD. \"The collaboration between Satellos and the FSHD Canada Foundation provides non-dilutive capital to advance forazapadin's clinical development in FSHD. Under the agreement, the Foundation has agreed to contribute up to US$5 million in milestone payments over the next five quarters in exchange for a capped revenue-sharing interest in future FSHD-related proceeds. The funds are expected to support the IND-cleared Phase 2 randomized, double-blind, placebo-controlled proof-of-concept clinical study designed to evaluate","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSLE","BK4585","LABU","BK4139","BMED","BK4588","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669456062","title":"Kringle Pharma Submits IND Application for Spinal Cord Injury Drug to U.S. FDA; Shares Jump 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669456062","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669456062?lang=en_us&edition=fundamental","pubTime":"2026-09-24 12:21","pubTimestamp":1790223665,"startTime":"0","endTime":"0","summary":"Kringle Pharma  submitted an Investigational New Drug  application to the U.S. Food and Drug Administration  to initiate a phase three clinical trial in the U.S. for acute spinal cord injury drug oremepermin alfa.The proprietary recombinant human HGF therapeutic, Oremepermin alfa, completed phase one/two and phase three trials in Japan for acute spinal cord injury, the late-stage clinical biopharmaceutical company said in a Thursday filing with the Japan bourse.The company is carrying out an additional Phase 3 trial to support a future regulatory submission, while the drug has secured orphan drug designation for acute SCI in Japan, the U.S. and Europe, it said.Shares of Kringle Pharma added nearly 7% in recent trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","BK7095","BK4585","IND","BK4588","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669771401","title":"Press Release: Sensorion Reports 2026 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2669771401","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669771401?lang=en_us&edition=fundamental","pubTime":"2026-09-23 13:30","pubTimestamp":1790141400,"startTime":"0","endTime":"0","summary":"--  Clinical Trial Applications  for SENS-601 , the. Company's lead gene therapy program for GJB2-related hearing loss were. filed in France and Canada, with Fast Track procedure granted in France;the Company subsequently received authorization from the French National. Agency for Medicines and Health Products Safety  to initiate the. --  Investigational New Drug  application in the United States and CTA. in Australia expected to be submitted by year-end 2026. --  Dosing of the first patient in HearConnex targeted by early 2027. --  Cash, cash equivalents and short-term deposits classified in current. assets amounted to EUR88 million as of June 30, 2026, expected to finance","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SENS","BK4082","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142880","title":"Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142880","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142880?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078400,"startTime":"0","endTime":"0","summary":"Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026 ADG138 is a double-masked T-cell engager, applying Adagene’s proprietary S","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/22/3366259/0/en/adagene-announces-nmpa-clearance-of-investigational-new-drug-application-for-adg138-a-novel-her2xcd3-double-masked-bispecific-t-cell-engager.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","LU0456854461.SGD","CRC","ADAG","BK4139","LU0266512127.USD","BK4213","BK4113","MSS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145358773","title":"Nomura Predicts India's Central Bank Net Forward Short Position Could Reach $232.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1145358773","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145358773?lang=en_us&edition=fundamental","pubTime":"2026-09-21 16:53","pubTimestamp":1789980831,"startTime":"0","endTime":"0","summary":"Strategists at Nomura, including Craig Chan, noted in a research report that based on data disclosed by the Reserve Bank of India, new foreign exchange inflows of $95.6 billion were recorded in...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVP","BK4523","IOPP","EPI","SMIN","PIN","IND","BK4585","INCO","BK4588","INDY","TAJX","INDA","INQQ","SCIN","NFTY","INDE","FLIBF","GIND","INDL","FLIN","NDIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669130288","title":"KBI DONGKOOK Extends KRW 17 Billion Debt Guarantee for German Auto Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2669130288","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669130288?lang=en_us&edition=fundamental","pubTime":"2026-09-21 14:19","pubTimestamp":1789971583,"startTime":"0","endTime":"0","summary":"KBI DONGKOOK IND CO., LTD. ( ($KR:001620) ) has issued an announcement. KBI DONGKOOK IND CO., LTD. has approved a debt guarantee for its German aff...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kbi-dongkook-extends-krw-17-billion-debt-guarantee-for-german-auto-subsidiary?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kbi-dongkook-extends-krw-17-billion-debt-guarantee-for-german-auto-subsidiary?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175783595","title":"Claim of 15.9 Million Turned Into a 150,000 Award: Court Fees Leave Plaintiff Holding Over 99% of the Tab in Drug Partner Dispute","url":"https://stock-news.laohu8.com/highlight/detail?id=1175783595","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175783595?lang=en_us&edition=fundamental","pubTime":"2026-09-20 21:11","pubTimestamp":1789909898,"startTime":"0","endTime":"0","summary":"A legal battle between two pharmaceutical companies over a contract worth just 5.58 million yuan has ended with a first-instance judgment of 150,600 yuan in damages, while the plaintiff bears more...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688202","BK0216","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668923031","title":"Xortx Therapeutics announces planned FDA IND submission for XRx-026","url":"https://stock-news.laohu8.com/highlight/detail?id=2668923031","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668923031?lang=en_us&edition=fundamental","pubTime":"2026-09-18 20:15","pubTimestamp":1789733736,"startTime":"0","endTime":"0","summary":"XORTX Therapeutics (XRTX) outlines its anticipated Investigational New Drug application, IND, submission to the U.S. Food and Drug Administration, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xortx-therapeutics-announces-planned-fda-ind-submission-for-xrx-026-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xortx-therapeutics-announces-planned-fda-ind-submission-for-xrx-026-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","LENZ","BK4539","BK4588","IND","LABU","BK4007","XRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108542280","title":"JPMorgan Warns of India's Short-Term Economic Euphoria, Urges RBI Caution on Rate Hikes","url":"https://stock-news.laohu8.com/highlight/detail?id=1108542280","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108542280?lang=en_us&edition=fundamental","pubTime":"2026-09-18 17:00","pubTimestamp":1789722058,"startTime":"0","endTime":"0","summary":"JPMorgan's Jahangir Aziz believes India's economy is experiencing a \"short-term euphoria\" driven by earlier stimulus measures, an effect that will eventually fade. He also cautioned that the market...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["US12M.BOND","TMF","FLIBF","INCO","INDL","MNDmain","INQQ","IND","US10Y.BOND","BK4523","US6M.BOND","US7Y.BOND","INDY","EMXC","US30Y.BOND","GLIN","BK4585","US2Y.BOND","INDE","US5Y.BOND","BKF","NFTY","IMVP","161121","NDIA","SMIN","US3Y.BOND","BK4582","BK4588","PGF","EPI","INDA","TLTW","FLIN","TAJX","TLT","SCIN","PIN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668753962","title":"NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution","url":"https://stock-news.laohu8.com/highlight/detail?id=2668753962","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668753962?lang=en_us&edition=fundamental","pubTime":"2026-09-17 20:00","pubTimestamp":1789646400,"startTime":"0","endTime":"0","summary":"Cash redemption simplifies the capital structure with no common shares issued in the redemptionCALABASAS, Calif., Sept.  17, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/17/3363907/0/en/neonc-technologies-redeems-all-outstanding-series-a-convertible-preferred-stock-and-eliminates-related-potential-dilution.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","CNS","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668298957","title":"Industrial Minerals Sets AGM Date and Board Nomination Deadline","url":"https://stock-news.laohu8.com/highlight/detail?id=2668298957","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668298957?lang=en_us&edition=fundamental","pubTime":"2026-09-17 16:17","pubTimestamp":1789633062,"startTime":"0","endTime":"0","summary":"Industrial Minerals Limited ( ($AU:IND) ) has issued an update. Industrial Minerals Ltd has scheduled its Annual General Meeting for 17 November 20...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-sets-agm-date-and-board-nomination-deadline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/industrial-minerals-sets-agm-date-and-board-nomination-deadline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MTX","IND","BK4109"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}